AMGEN INC. DL-,0001/ US0311621009 /
28/05/2024 08:09:25 | Chg. +0.60 | Volume | Bid11:48:42 | Ask11:48:42 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
281.60EUR | +0.21% | 0 Turnover: 0.00 |
280.85Bid Size: 70 | 281.75Ask Size: 90 | 151.09 bill.EUR | - | - |
GlobeNewswire
27/05
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...
GlobeNewswire
23/05
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
22/05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
21/05
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
21/05
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
15/05
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
14/05
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
14/05
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
13/05
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...